ALECARDIO trial halted for safety

Roche has halted a phase 3 trial of its investigational "glitazar" diabetes drug aleglitazar, being studied in diabetics with ACS, due to safety concerns. The drug seems to be following in the footsteps of two other agents in the class, which never made it to market.
Source: theHeart.org - Category: Cardiology Source Type: news